Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment.
Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment.
复制标题
DOI：
10.1038/nutd.2013.28
复制
发表时间：
2013-09-09
影响因子：
6.1
通讯作者：
Raoult, D.
中科院分区：
文献类型：
--
作者：
Million, M.;Thuny, F.;Angelakis, E.;Casalta, J-P;Giorgi, R.;Habib, G.;Raoult, D.
60年来，抗生素一直用于促进动物体重增加，当在婴儿早期使用时，它与成人和儿童的肥胖有关。罗伊氏乳杆菌与使用即食治疗食品的夸希奥科病儿童的肥胖和体重增加有关。相比之下，大肠杆菌与不肥胖有关。这两种细菌都对万古霉素耐药。我们评估了万古霉素相关的体重和肠道微生物群变化，并测试了先前与体重指数（BMI）相关的细菌种类是否预测了1年后的体重增加。纳入了2008年1月至2010年12月在我中心接受万古霉素或阿莫西林治疗的所有心内膜炎患者。使用实时PCR对在4-6周抗生素方案期间获得的样品定量拟杆菌、厚壁菌、乳杆菌和史氏甲烷短杆菌。L. n.罗伊特湖[医]植物rhamnosus、动物双歧杆菌（Bifidobacterium animalis）和E.在抗生素的第一周期间获得的粪便样品上定量大肠杆菌。在纳入研究的193名患者中，102名患者接受万古霉素治疗，91名患者接受阿莫西林治疗。万古霉素与BMI增加10%（比值比（OR）14.1; 95%置信区间（CI; 1.03-194）; P=0.047）和获得性肥胖（4/41 vs 0/56，P=0.01）相关。万古霉素组厚壁菌门、拟杆菌门和乳杆菌门均增加，而M. Smithii降低（P<0.05）。E.大肠杆菌是体重增加的独立预测因子（OR=10.7; 95%CI（1.4-82.0）; P=0.02）。令人惊讶的是，一个BMI增加18%的病人显示出L的急剧增加。reuteri，但E.杆菌在接受万古霉素治疗的患者中观察到的获得性肥胖可能与肠道微生物群的调节有关，而不是直接的抗生素作用。L. reuteri对万古霉素有抗性，并产生广泛的细菌素，可能在这种作用中起着重要作用。
Antibiotics, used for 60 years to promote weight gain in animals, have been linked to obesity in adults and in children when administered during early infancy. Lactobacillus reuteri has been linked to obesity and weight gain in children affected with Kwashiorkor using ready-to-use therapeutic food. In contrast, Escherichia coli has been linked with the absence of obesity. Both of these bacteria are resistant to vancomycin. We assessed vancomycin-associated weight and gut microbiota changes, and tested whether bacterial species previously linked with body mass index (BMI) predict weight gain at 1 year. All endocarditis patients treated with vancomycin or amoxicillin in our center were included from January 2008 to December 2010. Bacteroidetes, Firmicutes, Lactobacillus and Methanobrevibacter smithii were quantified using real-time PCR on samples obtained during the 4–6 weeks antibiotic regimen. L. reuteri, L. plantarum, L. rhamnosus, Bifidobacterium animalis and E. coli were quantified on stool samples obtained during the first week of antibiotics. Of the193 patients included in the study, 102 were treated with vancomycin and 91 with amoxicillin. Vancomycin was associated with a 10% BMI increase (odds ratio (OR) 14.1; 95% confidence interval (CI; 1.03–194); P=0.047) and acquired obesity (4/41 versus 0/56, P=0.01). In patients treated with vancomycin, Firmicutes, Bacteroidetes and Lactobacillus increased, whereas M. smithii decreased (P<0.05). The absence of E. coli was an independent predictor of weight gain (OR=10.7; 95% CI (1.4–82.0); P=0.02). Strikingly, a patient with an 18% BMI increase showed a dramatic increase of L. reuteri but no increase of E. coli. The acquired obesity observed in patients treated with vancomycin may be related to a modulation of the gut microbiota rather than a direct antibiotic effect. L. reuteri, which is resistant to vancomycin and produces broad bacteriocins, may have an instrumental role in this effect.
登录
查看更多内容
影响因子：
3.7
作者：
Armougom F;Henry M;Vialettes B;Raccah D;Raoult D
通讯作者：
Raoult D
影响因子：
11.8
作者：
Li, JS;Sexton, DJ;Corey, GR
通讯作者：
Corey, GR
影响因子：
10
作者：
Clement, A.;Tamalet, A.;Jais, J-P
通讯作者：
Jais, J-P
影响因子：
--
作者：
FLOOR, M;VANAKKEREN, F;VERHOEF, J
通讯作者：
VERHOEF, J
影响因子：
4.5
作者：
Kamada, T;Hata, J;Haruma, K
通讯作者：
Haruma, K